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OBJECTIVE: To estimate the cost-effectiveness of citico-
line in comparison to conventional therapy for the treat-
ment of patients with acute ischemic stroke. METHODS:
Decision tree analysis incorporating economic data and
results from alternative systematic reviews of effective-
ness. Data on effectiveness were obtained from a system-
atic review performed by the Cochrane Stroke Review
Group (CSRG) and a pooled analysis of primary data
from clinical trials sponsored by the Ferrer Group.
Resource use was obtained from a panel of experts based
in 5 Spanish hospitals. Unit costs were obtained from the
centres included in the study and from prices published
by the Spanish health care authorities. Two alternative
scenarios were considered: hospitalised patient and hos-
pitalised patient with ambulatory follow-up. Sensitivity
analysis of the key variables included was performed. The
time horizon for the study was 12 weeks. RESULTS: Even
in the most unfavourable scenario analysed, citicoline
proved to be an efﬁcient treatment option in patients with
acute ischemic stroke. Citicoline led to increases in the
proportion of patients without discapacity of between
5% and 10%, compared to conventional treatment.
Based on the efﬁcacy ﬁgures reported by the CSRG, the
cost per patient treated with citicoline was €3026.12
when only hospitalisation was taken into account, while
the equivalent cost per patient receiving placebo was
€3127.34. When the costs of ambulatory follow-up were
added, the cost per patient increased to €3663.50 in 
the citicoline group and €3795.90 in patients receiving
placebo. CONCLUSION: Citicoline is an effective and
efﬁcient treatment alternative in the management of
stroke patients, in all of the scenarios analysed.
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OBJECTIVES: Timely detection of renal artery stenosis
(RAS) is important as it may cause renovascular hyper-
tension and renal impairment. In the Renal Artery Diag-
nostic Imaging Study in Hypertension (RADISH), 402
patients suspected of having RAS were submitted to 
computed tomographic angiography (CTA), magnetic 
resonance angiography (MRA) and digital subtraction
angiography (DSA), in order to investigate the diagnostic
performance of CTA and MRA. Providing policy makers
and clinicians with information about the costs associated
with applying different diagnostic imaging strategies for
detecting RAS is important. Therefore, also a compara-
tive short-term cost analysis was performed. METHODS:
The analysis involved three diagnostic strategies: 1) direct
DSA; 2) CTA ± DSA, and 3) MRA ± DSA. Strategies 2
and 3 included DSA as the gold standard to conﬁrm the
diagnosis. After a negative CTA or MRA test result no
further tests were performed. The cost calculations were
performed from the societal perspective. Data were ana-
lyzed using a decision model, combining original patient
data and medical literature data. Short-term costs were
deﬁned as costs occurring during the ﬁrst year after treat-
ment, including the diagnostic work-up and revascular-
ization procedure. RESULTS: The strategy, whereby
patients are referred for DSA only in case of a positive
CTA test result was the least costly option (€2286), fol-
lowed by MRA ± DSA and direct DSA (€2598 and €3695,
respectively). CONCLUSIONS: Considered from the cost
perspective, CTA followed by DSA only in case of a pos-
itive test result is the strategy of choice. However, the cost
consequences of false negative test results were not con-
sidered since these effects generally reveal in the long
term. Also, health beneﬁts in terms of quality of life 
and life expectancy were not included in the analysis.
Therefore, a cost-effectiveness Markov model, including
short and long term costs and health effects, is currently
built.
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OBJECTIVES: In the Irbesartan in Diabetic Nephropa-
thy Trial (IDNT), treatment with irbesartan demonstrated
23% and 20% reductions in the combined endpoint 
of doubling of serum creatinine (DSC), end-stage renal
disease (ESRD) or death in patients with hypertension,
type 2 diabetes, and overt nephropathy compared to
amlodipine and control respectively. A simulation model
was developed to project long-term cost consequences of
the IDNT in Hungary. METHODS: A Markov model
simulated progression from nephropathy to DSC, ESRD,
and death in patients with hypertension, type 2 diabetes
and overt nephropathy. Treatment-speciﬁc probabilities
were derived from IDNT. Hungarian-speciﬁc ESRD-
related data were retrieved from local databases. Delay in
onset of ESRD, life expectancy and mean lifetime costs
were calculated for patients with baseline age 59 years.
Future costs were discounted at 5% per annum, and clin-
ical beneﬁts were discounted at 0% and 5% per annum.
Extensive sensitivity analyses were performed. RESULTS:
Onset of ESRD was delayed with irbesartan by 1.41 and
1.35 years versus amlodipine and control respectively.
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Cumulative incidences of ESRD were 54.7%, 59.3% and
46.7% for control, amlodipine, and irbesartan respec-
tively.When a 25-year (lifetime) horizon was considered,
delay in ESRD onset led to anticipated improvements in
life expectancy (discounted results shown in brackets) of
0.29 (0.15) years versus amlodipine and 0.63 (0.36) years
versus control. Irbesartan led to cost savings of Hun-
garian Forint (HUF) 2,698,826 (€10,267) and HUF
1,605,897 (€6,109) per patient versus amlodipine and
control respectively. The results were robust under a wide
range of plausible assumptions. CONCLUSIONS: Treat-
ing patients with hypertension, type 2 diabetes and overt
nephropathy using irbesartan was both cost- and life-
saving compared to amlodipine and control in the 
Hungarian setting.
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OBJECTIVE: More than 5.4 million Russian patients
have an history of Ischemic Heart Disease and this
accounts for 26% of all deaths every year. The CURE 
trial demonstrated the efﬁcacy of clopidogrel in ACS, vs
placebo, both group received standard therapy including
ASA. This evaluation was performed to assess the cost-
effectiveness of clopidogrel in Russia based upon the
CURE trial. METHODS: Resource use (hospitalisations,
procedures, comedications, study drugs) was collected in
the Case Report Form of the clinical trial. Costs of med-
ications were based on cost per day of study drugs and
average cost per day of the different therapeutic classes
for comedications. Hospitalisations costs including the
costs of stay at an intensive care unit were calculated 
from Russian medicoeconomic standards. The efﬁcacy
outcome was the number of total events prevented (car-
diovascular deaths, myocardial infarctions, and strokes).
Cost-effectiveness was expressed as the cost per event
avoided with clopidogrel plus ASA versus ASA alone. All
costs were calculated in 2002 prices. The Russian ruble-
to-US dollar exchange rate used was 31.3. RESULTS:
During the 12-month study period, the CURE trial
showed that patients treated with clopidogrel had signif-
icantly lower rates of cardiovascular events (11.14% vs
13.15%). The mean cost per patient was higher with
clopidogrel ($2,425.60) than with standard therapy
($18,82.80). The difference of $542.80 was primarily due
to a higher acquisition cost of clopidogrel. Nevertheless
total cost of hospitalisations was lower in the clopidogrel
arm ($1119 vs $1149). The estimated incremental cost
per event avoided was $27,000. CONCLUSION: This
analysis showed that clopidogrel on top of standard
therapy including ASA, for ACS, results in a favourable
cost-effectiveness ratio in terms the cost per event avoided
compared to other cardiovascular drugs. These data
provide strong arguments for the choice of a treatment
for ACS in the public health care system.
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OBJECTIVES: The Clinical Decision Support Systems
(CDSS) can be intended as tools to improve the health
care. The Optimcare Study objectives are to implement a
clinical guideline to manage hypercholesterolemic patients
on a CDSS and to assess its impact in cost-effectiveness
terms, in usual practice conditions. METHODS:
Naturalistic and unicentric design in which a therapeuti-
cally intervention including a CDSS and a ﬂexible patient
education was applied and compared between two periods
in a patient cohort. Five hundred hypercholesterolemic
patients (ICD9-CM code = 272.0) were randomiously
selected from the Primary Health Care center database
(CAP Vila Olímpica, Barcelona, Spain). The CDSS imple-
mented algorithms agreed by the participating physicians,
with therapeutical recommendations to achieve cLDL
objectives in a cost-effective manner. The compared
periods were the year before (PRE) and the year after (POS)
the ﬁrst visit in which physicians could access to the CDSS
from their physician desk. The clinical and resources con-
sumption data in PRE were obtained from the center data-
base. The effectiveness was assessed through the
therapeutical objective achievement in PRE and POS
periods referred to the clinical guideline objectives. The
costs were assessed from the social perspective. RESULTS:
The therapeutical objective achievement increased an
11.9% (54,2% PRE vs 66.1% POS). While cLDL
decreased 10mg/dl (CI 95% -14 to -6). The number of
pharmacologically treated patients decreased a 14.6%
(76.5% PRE vs 61.9% POS). The patient mean total costs
were decreased in POS period [difference = €78.4 (IC 95%
-94.7 to -62.1)]. Considering all the visits the adherence
to the therapeutical recommendations were a 88.4% while
showed a decrease until 72.5% when next visit dates rec-
ommendations were considered. CONCLUSIONS: The
CDSS given recommendations were accepted by the 
physician in a high degree and were shown as more cost-
effective than the usual care practice.
